Insights AI in Practice AI in Oncology Decision-Making Support

AI in Oncology: From Diagnosis to Human Connection

April 03, 2026 By Sarah Sammons, MD 2 min read
Share Share via Email Share on Facebook Share on LinkedIn Share on Twitter

I’ve been thinking a lot about how AI will transform oncology.

I think second opinions will take a hit. The diagnostic pattern-matching that defines the role today, reading scans, matching tumor profiles to treatments is exactly what AI will commoditize first.

As AI absorbs the cognitive load of diagnosis, the irreducibly human skills move to the center: reasoning through genuine uncertainty, sitting with a patient in a hard conversation, explaining trade-offs to a frightened family, making judgment calls where the data runs out.

We’ve spent decades training physicians to think like computers. Now we need them to think like humans again. We will need to become MORE HUMAN.

The doctors who thrive won’t be the ones who know the most. They’ll be the ones who can reason out loud, communicate clearly, and connect. The centers with the best supportive care and operations will win out.

Is medical education ready for that shift?

Sarah Sammons, MD, is Associate Director, Breast Cancer Program at Dana-Farber Cancer Institute, and Assistant Professor of Medicine at Harvard Medical School in Boston, Massachusetts. 

Disclaimer: This commentary represents the views of the author and may not necessarily reflect the views of ASCO, Conexiant, or ASCO AI in Oncology.

Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results of a recent study published in JAAD International.

“This type of cancer, which is a result of mutations of the most common cell type in the top layer of the skin, is strongly linked to accumulated [ultraviolet] radiation over time. It develops in sun-exposed areas, often on skin already showing signs of sun damage, with rough scaly patches, uneven pigmentation, and decreased elasticity,” stated lead researcher Sam Polesie, MD, PhD, Associate Professor of Dermatology and Venereology at the University of Gothenburg and Practicing Dermatologist at Sahlgrenska University Hospital, both in Gothenburg, Sweden.

KOL Commentary
Watch

Related Content